520 Results

People

  1. Postow
    Postow
  2. Motzer
    Motzer
  3. Wolchok
    Wolchok
  4. Hellmann
    Hellmann
  5. Shoushtari
    Shoushtari
  6. Voss
    Voss
  7. Callahan
    Callahan
  8. Abou-Alfa
    Abou-Alfa
  9. Jones
    Jones
  10. Rosenberg
    Rosenberg

Groups

  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)
  7. GSK Faculty (83)
  8. Surgery (71)
  9. Gastrointestinal Oncology Service (65)
  10. Weinberg Fellows (61)
  1. "nivolumab"
Formats
  1. Journal Article (342)
  2. Review (93)
  3. Editorial (41)
  4. Meeting Abstract (18)
  5. Correspondence (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Book Section (4)
  9. Conference Paper (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (394)
  2. Solid Tumor Oncology Division (337)
  3. Hematologic Malignancies, Division of (108)
  4. Melanoma and Immunotherapeutics Service (108)
  5. Genitourinary Oncology Service (101)
  6. Melanoma Disease Management Team (96)

More Groups

People
  1. Michael Postow (55)
  2. Robert Motzer (50)
  3. Jedd Wolchok (41)
  4. Margaret Callahan (28)
  5. Alexander Shoushtari (27)
  6. Matthew Hellmann (26)

More People

Years
  1. 2025 (35)
  2. 2024 (70)
  3. 2023 (75)
  4. 2022 (52)
  5. 2021 (45)
  6. 2020 (64)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (23)
  2. Journal of Clinical Oncology (22)
  3. Journal of Thoracic Oncology (21)
  4. Lancet Oncology (21)
  5. New England Journal of Medicine (19)
  6. Annals of Oncology (17)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. Elsevier Science, Inc. (50)
  3. Oxford University Press (35)
  4. Wiley Blackwell (32)
  5. Biomed Central Ltd (27)
  6. Nature Publishing Group (27)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
    Journal Article

    Eroglu, Z.; Broman, K. K.; Thompson, J. F.; Nijhuis, A.; Hieken, T. J.; Kottschade, L.; Farma, J. M.; Hotz, M.; Deneve, J.; Fleming, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Journal Article

    Omuro, A.; Reardon, D. A.; Sampson, J. H.; Baehring, J.; Sahebjam, S.; Cloughesy, T. F.; Chalamandaris, A. G.; Potter, V.; Butowski, N.; Lim, M.
    Neuro-Oncology Advances (2022)

    Fulltext@MSK | Save
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
    Journal Article

    Sanborn, R. E.; Pishvaian, M. J.; Callahan, M. K.; Weise, A.; Sikic, B. I.; Rahma, O.; Cho, D. C.; Rizvi, N. A.; Sznol, M.; Lutzky, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial
    Journal Article

    Albiges, L.; Tannir, N. M.; Burotto, M.; McDermott, D.; Plimack, E. R.; Barthélémy, P.; Porta, C.; Powles, T.; Donskov, F.; George, S.; more...
    European Urology (2022)

    Fulltext@MSK | Save
  • Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm
    Editorial

    Cameron, R. B.; Ajani, J. A.; Wu, A. J.
    Journal of Thoracic and Cardiovascular Surgery (2022)

    Fulltext@MSK | Save
  • Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
    Review

    Silk, T.; Silk, M.; Wu, J.
    World Journal of Gastroenterology (2022)

    Fulltext@MSK | Save
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C. M.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Interpreting nonrandomized clinical trial data in low-grade sarcoma: Differentiating clinical benefit from indolent disease is key
    Correspondence

    Rosenbaum, E.; Movva, S.; Kelly, C.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma
    Journal Article

    Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Song, X.; Kuziora, M.; Meinecke, L.; Blando, J.; Achour, I.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save